ReviewJournal of kidney cancer and VHL2022
New Trends and Evidence for the Management of Renal Angiomyolipoma: A Comprehensive Narrative Review of the Literature.
Review in Journal of kidney cancer and VHL, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 4 citations in OpenAlex.
- From the spectrum of PEComa: a renal angiomyolipoma.Journal of surgical case reports · 2026Article
- Article
- Development of a clinical nomogram for predicting hemorrhagic rupture in renal angiomyolipoma and analysis of molecular correlates (Open medicine (Warsaw, Poland) · 2026Article
- Spontaneous retroperitoneal bleeding from rupture of a massive renal angiomyolipoma managed with transcatheter arterial embolization.Radiology case reports · 2025Article
- Comparison of perioperative efficacy and indications between laparoscopic capsule-preserving resection and partial nephrectomy for renal angiomyolipoma: a decade-long retrospective study.World journal of surgical oncology · 2025Article
- The prospect of novel orphan therapeutic protocol for TSC2/PKD1 contiguous gene syndrome: a case report.BMC nephrology · 2025Article
- Higher Risk Renal Angiomyolipomas: Surveillance Remains a Safe Management Option.Urology practice · 2025Article
- Postembolization syndrome in a patient with a giant renal angiomyolipoma: A case report.Radiology case reports · 2024Article
- Surgical excision of recurrent renal angiomyolipoma after previous embolization and nephron-sparing surgery - A case report.International journal of surgery case reports · 2024Article
- Article
- Endovascular Treatment of a Bilateral, Ruptured Angiomyolipoma in a Patient With Tuberous Sclerosis Complex.Cureus · 2024Article
- Sesame Seeds: A Nutrient-Rich Superfood.Foods (Basel, Switzerland) · 2024Review
- A Case of Life-threatening Rupture of Small Renal Angiomyolipoma with an Unidentified Intratumoral Aneurysm during Follow-up.Interventional radiology (Higashimatsuyama-shi (Japan) · 2024Article
- Spontaneous rupture of renal angiomyolipoma presenting with shock; a case report from Tanzania.International journal of surgery case reports · 2023Article
- Is Size All That Matters? New Predictors of Complications and Bleeding in Renal Angiomyolipoma.Research and reports in urology · 2023Article
- Ruptured angiomyolipoma, a novel entity for emergency physicians in the differential diagnosis of haemorrhagic shock in a female patient of reproductive age.BMJ case reports · 2022Article
- Case report: A hybrid technique for a safe nephrectomy in a giant kidney angiomyolipoma.Frontiers in surgery · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of renal angiomyolipoma (AML) seeks to reduce related complications and preserve kidney function. The purpose of this article was to perform an updated literature review on the diagnosis, therapeutic options, and criteria for invasive intervention in patients with renal AML. Computerized tomography is the standard diagnostic method for renal AML, while definitive diagnosis is made by histopathology. The management of choice in most cases is active surveillance (AS), with a clinical and imaging follow-up protocol. In high-risk cases, therapeutic management should be considered, with alternatives such as selective arterial embolization (SAE), nephron-sparing surgery (NSS), and mTOR inhibitors in selected patients. Renal AML in women of childbearing age, those with growth >0.25 cm/year, intralesional aneurysms >5 mm, and clinically significant symptoms may qualify for active treatment. Despite the limitations derived from the available evidence, it is possible to consider SAE, NSS, and the use of mTOR inhibitors as management alternatives for selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.